Under construction – not a live service
Sign in
Taking peoplePhase 2

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

Key facts

Phase
Phase 2

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07172347, who can take part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Jiangsu vcare pharmaceutical technology co., LTD
Trial code
NCT07172347
Record updated
2 January 2026
Original description
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical studyRead full original descriptionShow less

A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Inclusion: The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol; The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.

Exclusion: Subjects who have previously received depigmentation treatment; Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization; Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs; Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period; All hair in the vitiligo area on the face is white.

ClinicalTrials.gov NCT07172347